Key result
Xience Prime stent demonstrates a ~5% MACE rate at two years in long coronary lesions.
Why the study?
Long coronary lesions are technically challenging with first-generation DES associated with high MACE rates, and limited data exist on second-generation DES performance in this subset.
Observational (n=610)
Yes
The use of second-generation everolimus-eluting stents in long coronary lesions demonstrates excellent efficacy and safety with low rates of MACE and stent thrombosis up to 24 months.
Supports Xience Prime in long lesions; hypothesis-generating and should not change practice without randomized data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Fernández et al. (2018) conducted an observational in Long coronary lesions (n=610). Xience Prime everolimus-eluting stent (EES) was evaluated on Major adverse cardiac events (MACE; cardiac death, myocardial infarction, and target lesion revascularization) at 24 months. In a real-world registry of patients with long coronary lesions, the Xience Prime everolimus-eluting stent demonstrated a 24-month MACE rate of 5.4% and a stent thrombosis rate of 1.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: